Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.65 +0.52 (+2.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why.
Viking Therapeutics may be the next company to enter the red-hot weight loss space. 
Via The Motley Fool
Groundbreaking Documentary ‘Project Whistleblower’ Pulls Back the Curtain on Corporate Misconduct
Via Press Release Distribution Service
Topics Whistleblower
Exposures Legal
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Spring Cleaning Alert: 7 Dreadful Stocks to Ditch Now
There’s no time like the present to rid your portfolio of underperforming stocks to sell. Avoid these stocks to have a successful 2024. 
Via InvestorPlace
7 Dividend Stocks to Secure Your Financial Freedom by 2026
Explore seven dividend stocks for financial freedom in banking, insurance, construction, pharmaceuticals, and telecommunications. 
Via InvestorPlace
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
Study Questions Serious Flaws in $35 Million Antidepressant Research
CCHR says millions of taxpayer dollars are wasted on psychotropic drug research later found to be flawed and harmful to consumersLOS ANGELES - March 22, 2024 - PRLog -- Researchers have reanalyzed data... 
Via PRLog
Topics Fraud
Exposures Legal Product Safety
Pfizer Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Is Pfizer the Best Dividend Stock for You?
Pfizer's stock is cheap, and it pays an incredibly high yield right now. 
Via The Motley Fool
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
The 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months
Let's review what Wall Street analysts believe are potentially the stocks to double over the next 12 months. 
Via InvestorPlace
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000
Each of these three companies are entering a new era of growth. 
Via The Motley Fool
Adobe Revolutionizes Content Supply Chain With New Generative AI Tools
Adobe introduces GenStudio and Firefly, a suite of AI tools that streamline content creation and management, addressing the challenges of the content supply chain. Strategic partnerships and new... 
Via Benzinga
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Supply Chain
Harnessing AI for Drug Discovery: Top 3 Stocks to Watch
As biotech innovators look to AI to smoothen out the drug discovery process, the leaders in the scene could stand to benefit greatly. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold Forever
If you have a Benjamin burning a hole in your pocket, these stocks are a great way to invest it. 
Via The Motley Fool
Buffett’s Backdoor Buys: 3 Stocks His Secret Portfolio Is Quietly Accumulating
Warren Buffett stocks and Berkshire Hathaway's portfolio of companies are hidden investment vehicles hiding in plain sight. 
Via InvestorPlace
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants. 
Via The Motley Fool
3 Ultra-High-Yield Dividend Stocks That Could Realistically Double Your Money by 2030
There's no guarantee these stocks can generate 100% returns by 2030. But they have a clear path to make it happen. 
Via The Motley Fool
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?
What's good for Wood and Ark Invest might not be good for other investors. 
Via The Motley Fool
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks. 
Via The Motley Fool
7 Stocks That Will Make Your Friends Green with Envy
Discover stocks set to dazzle the market with innovative business models and disruptive technologies. Dive in for potential outperformance. 
Via InvestorPlace
A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now
These stocks share several things in common. 
Via The Motley Fool
2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?
After a lousy year of declining prices, these stocks offer yields of 4.7% and 6.1% at recent prices. 
Via The Motley Fool
Will Pfizer Be a Trillion-Dollar Stock by 2035?
A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable. 
Via The Motley Fool
7 High-Value Stocks With Massive Wealth-Building Potential
Explore high-value stocks shaping the future across semiconductors, digital payments, AI, and healthcare for savvy investors. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
Legal actions surge against diabetes drug manufacturers Eli Lilly and Novo Nordisk. Patients allege severe complications, including gallbladder issues and gastroparesis, tied to GLP-1 agonists. Over 60... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Spinal Delivery Of Taysha's Gene Therapy Shows Promise In Rare Childhood Neurodegenerative Disease
Promising results from a Phase 1 trial led by NIH: scAAV9/JeT-GAN gene therapy shows potential benefits for giant axonal neuropathy. The therapy demonstrated safety and efficacy in children with GAN,... 
Via Benzinga
Is Cathie Wood Buying The Rumor? Ark More Than Doubles Stake In This COVID-19 Vaccine Maker Ahead Of Flurry Of Catalysts
Ark, through its flagship Ark Innovation ETF and Ark Genomic Revolution ETF, has been brisk with its acquisition of Moderna shares in March. 
Via Benzinga
Topics ETFs
Exposures COVID-19
EXCLUSIVE: Health Care Experts Discuss Critical Need For An Equitable System
Former Pfizer CMO Dr. Freda Lewis-Hall and ICR Westwicke's Michael O'Brien discuss challenges in autoimmune disease treatment and healthcare innovation. 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.